<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This review describes the effect of lifestyle change or <z:chebi fb="0" ids="6801">metformin</z:chebi> compared with standard care on incident type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and cardiometabolic risk factors in the <z:mp ids='MP_0002055'>Diabetes</z:mp> Prevention Program and its Outcome Study </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:mp ids='MP_0002055'>Diabetes</z:mp> Prevention Program was a randomized controlled clinical trial of intensive lifestyle and <z:chebi fb="0" ids="6801">metformin</z:chebi> treatments versus standard care in 3234 subjects at high risk for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>At baseline, <z:hpo ids='HP_0000822'>hypertension</z:hpo> was present in 28% of subjects, and 53% had <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> with considerable variation in risk factors by age, sex, and race </plain></SENT>
<SENT sid="3" pm="."><plain>Over 2.8 years, type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> incidence fell by 58% and 31% in the lifestyle and <z:chebi fb="0" ids="6801">metformin</z:chebi> groups, respectively, and <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> prevalence fell by one-third with lifestyle change but was not reduced by <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>In placebo- and <z:chebi fb="0" ids="6801">metformin</z:chebi>-treated subjects, the prevalence of <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> increased during the <z:mp ids='MP_0002055'>Diabetes</z:mp> Prevention Program, whereas lifestyle intervention slowed these increases significantly </plain></SENT>
<SENT sid="5" pm="."><plain>During long-term follow-up using modified interventions, type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> incidence decreased to â‰ˆ5% per year in <z:hpo ids='HP_0000001'>all</z:hpo> groups </plain></SENT>
<SENT sid="6" pm="."><plain>This was accompanied by significant improvement in <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> risk factors over time in <z:hpo ids='HP_0000001'>all</z:hpo> treatment groups, in part associated with increasing use of <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering and <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> medications </plain></SENT>
<SENT sid="7" pm="."><plain>Thus a program of lifestyle change significantly reduced type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> incidence and <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> prevalence in subjects at high risk for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> had more modest effects </plain></SENT>
</text></document>